Harrow Inc. (HROW)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Harrow: Epic Growth & Operating Leverage On Full Display
Harrow has successfully leveraged its compounding pharmacy roots to drive rapid branded drug growth. Revenue has grown at a steady 40% CAGR for a decade & EBITDA has grown even more sharply. Management is guiding for this to not only continue, but actually accelerate. Harrow's operating leverage is plainly evident in the data. EBITDA margins have risen sharply as the company has grown, and management has guided for this to accelerate in 2025.
Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript
Harrow, Inc. (NASDAQ:HROW ) Q1 2025 Results Conference Call May 9, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Chase Knickerbocker - Craig Hallum Jeffrey Cohen - Ladenburg Thalmann and Company Yi Chen - H. C. Wainwright Mayank Mamtani - B.
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
Harrow (HROW) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.28 per share a year ago.
Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex reimbursement challenges and tough competition. Valuation models suggest Harrow is fairly valued if it achieves 20% revenue growth and 15% FCF margins, though these are lofty expectations.
Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call
Harrow, Inc. (NASDAQ:HROW ) Q4 2024 - Earnings Conference Call March 28, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Thomas Flaten - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann and Company Mayank Mamtani - B. Riley Securities Yi Chen - H.
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp
Harrow, Inc. is a speculative buy, with potential trading gains from the $20s to the $30s, and long-term growth prospects. The company reported strong Q4 growth, with an 84% revenue increase and improved gross profit margins, driven by key products IHEEZO and VEVYE. Harrow's 2025 revenue guidance is bullish, expecting over $280 million, a 40% increase, supported by the VEVYE Access for All program.
Harrow (HROW) Q4 Earnings and Revenues Top Estimates
Harrow (HROW) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.27 per share a year ago.
Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025
Harrow Health's robust distribution platform and patented eye care products create a strong moat, offering an attractive entry point after the recent stock price correction. Catalysts in 2025 could come from a successful Triesence launch and potential NDA filing for Melt pharma, where HROW has a material stake. The main risk is the company's loss in Q3 2024 despite recent acquisitions, so more revenue growth alongside controlled costs is needed for the stock to work from here.
Those Derisked Baby Bonds Of Harrow, Inc.
Harrow's 11.875% Senior Notes due 2027 are attractive baby bonds with a healthy leverage percentage of 13.8%, indicating strong creditworthiness and low debt. Harrow funds operations through product sales, not debt or frequent equity raises, showcasing a robust financial position and sustainable business model. VEVYE, IHEEZO, and Triesence show significant growth potential, with Triesence addressing supply chain issues and justified price hikes, ensuring strong future demand.
Harrow: The Triesence Relaunch
Harrow's relaunch of Triesence, a preservative-free corticosteroid, addresses a critical unmet need in ophthalmology, offering safer and more effective treatment options for eye care professionals. Triesence's unique formulation and absence of preservatives make it superior to alternatives like Kenalog, despite its higher price point and previous supply chain issues. Harrow's acquisition and relaunch of Triesence, with 39,000 units available, positions the company for significant market growth, targeting over 500,000 units annually.
Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript
Harrow, Inc. (NASDAQ:HROW ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Jamie Webb - Director, Communications & Investor Relations Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann & Company Mayank Mamtani - B. Riley Securities Operator Good morning, and welcome to Harrow's Third Quarter 2024 Earnings Conference Call.
Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates
Harrow (HROW) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.
